Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.

Valeria Santini, Thomas Prebet, Pierre Fenaux, Norbert Gattermann, Lars Nilsson, Michael Pfeilstöcker, Paresh Vyas, Alan F List

    Forskningsoutput: TidskriftsbidragÖversiktsartikelPeer review

    27 Citeringar (SciVal)

    Sammanfattning

    In Europe, azacitidine is the only hypomethylating agent approved for the treatment of patients with int-2-/high-risk myelodysplastic syndromes, offering significantly improved survival compared with conventional care. However, not all patients treated with azacitidine respond to treatment, and the vast majority of responders subsequently relapse. Currently, no standard care regimens have been established for patients after failure of azacitidine. Here, we discuss treatment options after loss of response or progression on azacitidine. In addition, we briefly consider optimization of first-line treatment along with potential biomarkers for identifying and monitoring response during treatment with azacitidine.
    Originalspråkengelska
    Sidor (från-till)1381-1391
    TidskriftLeukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis
    Volym38
    Utgåva12
    DOI
    StatusPublished - 2014

    Ämnesklassifikation (UKÄ)

    • Cancer och onkologi

    Fingeravtryck

    Utforska forskningsämnen för ”Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.”. Tillsammans bildar de ett unikt fingeravtryck.

    Citera det här